News & Views
Telix announces its subsidiary, Telix Pharmaceuticals Japan KK, has entered a clinical study collaboration with Kanazawa University (Japan) for the conduct of a Phase I trial of its prostate cancer…
Read more
Telix Pharmaceuticals Limited announces today that its wholly-owned subsidiary TheraPharm GmbH has completed an Intellectual Property (IP) agreement with the University of Southampton,…
Read more
Telix has been granted Priority Review status for TLX591-CDx (68Ga-PSMA-11), a radiopharmaceutical for the imaging of prostate cancer using Positron Emission Tomography…
Read more
Telix Pharmaceuticals announces it has entered into a licensing and partnership agreement with…
Read more
Telix has been granted HREC approval and received CTN clearance by the TGA to commence Phase I study of the Company’s next generation prostate cancer therapy product TLX592, in patients…
Read more
Telix Pharmaceuticals Provides Investor Briefing: TheraPharm GmbH…
Read more
Telix advises it will hold an investor conference call to provide further detail in relation to Telix’s acquisition of TheraPharm…
Read more
Telix announces it has entered into an agreement with Scintec Diagnostics GmbH to acquire TheraPharm GmbH, a Swiss-German biotechnology company developing innovative diagnostic and therapeutic solutions in the field of…
Read more
Telix Pharmaceuticals announces New Drug Application (NDA) for TLX591-CDx (Kit for the preparation…
Read more
Telix recently presented at the 12th European Multidisciplinary Congress on Urological Cancers entitled: “New Perspectives in Prostate and Kidney…
Read more